

# Juhaeri Juhaeri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1550168/publications.pdf>

Version: 2024-02-01

40  
papers

954  
citations

471509

17  
h-index

477307

29  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1355  
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance assessment of different machine learning approaches in predicting diabetic ketoacidosis in adults with type 1 diabetes using electronic health records data. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 610-618.	1.9	10
2	Evaluating the Risk of Digitalis Intoxication Associated With Concomitant Use of Dronedaronone and Digoxin Using Real-World Data. <i>Clinical Therapeutics</i> , 2021, 43, 852-858.e2.	2.5	0
3	Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1353-1359.	1.9	4
4	Incidence of diabetic ketoacidosis and its trends in patients with type 1 diabetes mellitus identified using a U.S. claims database, 2007-2019. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107932.	2.3	4
5	Age- and sex-specific incidence of non-traumatic lower limb amputation in patients with type 2 diabetes mellitus in a U.S. claims database. <i>Diabetes Research and Clinical Practice</i> , 2020, 169, 108452.	2.8	9
6	Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature. <i>Therapeutic Advances in Drug Safety</i> , 2020, 11, 204209862097695.	2.4	8
7	Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 114.	3.0	26
8	Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance. <i>Therapeutic Advances in Drug Safety</i> , 2019, 10, 204209861986474.	2.4	21
9	Comparison of text processing methods in social media-based signal detection. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1309-1317.	1.9	9
10	Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US. <i>Frontiers in Pharmacology</i> , 2019, 10, 1009.	3.5	16
11	Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 189.	3.0	36
12	Benefit-risk evaluation: the past, present and future. <i>Therapeutic Advances in Drug Safety</i> , 2019, 10, 204209861987118.	2.4	22
13	Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA. <i>Patient</i> , 2019, 12, 513-526.	2.7	24
14	Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. <i>Drug Discovery Today</i> , 2019, 24, 1324-1331.	6.4	90
15	Proximal HbA1C Level and First Hypoglycemia Hospitalization in Adults With Incident Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1989-1998.	3.6	2
16	Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study. <i>Frontiers in Pharmacology</i> , 2019, 10, 1395.	3.5	48
17	Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review. <i>Drug Discovery Today</i> , 2019, 24, 57-68.	6.4	69
18	Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedaronone Compared With That in Other Antiarrhythmics. <i>Clinical Therapeutics</i> , 2018, 40, 450-455.e1.	2.5	8

#	ARTICLE	IF	CITATIONS
19	Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998â€“2013: A Retrospective Cohort Study. <i>Diabetes Care</i> , 2018, 41, 1870-1877.	8.6	101
20	HbA 1C variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: A nested case-control study. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 203-209.	2.3	17
21	Web-Based Signal Detection Using Medical Forums Data in France: Comparative Analysis. <i>Journal of Medical Internet Research</i> , 2018, 20, e10466.	4.3	22
22	Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS. <i>Drug Safety</i> , 2017, 40, 399-408.	3.2	13
23	Dietary intake and risk of non-severe hypoglycemia in adolescents with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1340-1347.	2.3	15
24	Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998â€“2013: A Retrospective Cohort Study. <i>Diabetes Care</i> , 2017, 40, 1651-1660.	8.6	49
25	The US Food and Drug Administrationâ€™s Risk Evaluation and Mitigation Strategy (REMS) Program â€“ Current Status and Future Direction. <i>Clinical Therapeutics</i> , 2016, 38, 2526-2532.	2.5	17
26	The risk of acute liver injury associated with the use of antibioticsâ€”evaluating robustness of results in the pharmacoepidemiological research on outcomes of therapeutics by a European consortium (PROTECT) project.. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 47-55.	1.9	9
27	Recommendations for benefitâ€“risk assessment methodologies and visual representations. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 251-262.	1.9	51
28	Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 97-104.e7.	2.9	28
29	Benefitâ€“Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1233-1240.	1.9	23
30	Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm. <i>Cancer Epidemiology</i> , 2015, 39, 242-249.	1.9	16
31	Benefitâ€“risk assessment in a postâ€“market setting: a case study integrating realâ€“life experience into benefitâ€“risk methodology. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 974-983.	1.9	17
32	Assessment of Dronedaronone Utilization Using US Claims Databases. <i>Clinical Therapeutics</i> , 2014, 36, 264-272.e2.	2.5	7
33	Abstract 18020: Identifying Hospitalizations Related to Heart Failure in Dronedaronone Users Who Are Supplementary Medicare Beneficiaries. <i>Circulation</i> , 2014, 130, .	1.6	0
34	Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedaronone versus Amiodarone and Other Antiarrhythmics. <i>Journal of Atrial Fibrillation</i> , 2013, 6, 890.	0.5	13
35	Evaluation of Dronedaronone Use in the US Patient Population Between 2009 and 2010: A Descriptive Study Using a Claims Database. <i>Clinical Therapeutics</i> , 2011, 33, 1483-1490.e3.	2.5	6
36	Predicting the risk of end-stage renal disease in the population-based setting: a retrospective case-control study. <i>BMC Nephrology</i> , 2011, 12, 17.	1.8	23

#	ARTICLE	IF	CITATIONS
37	Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 497-503.	1.9	33
38	The Incidence Rate of Seizures in Relation to BMI in UK Adults. <i>Obesity</i> , 2008, 16, 2126-2132.	3.0	10
39	Benefit-risk analysis: examples using quantitative methods. <i>Pharmacoepidemiology and Drug Safety</i> , 2003, 12, 693-697.	1.9	25
40	Benefit-risk analysis: a proposal using quantitative methods. <i>Pharmacoepidemiology and Drug Safety</i> , 2003, 12, 611-616.	1.9	53